Carla J Treloar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6333809/publications.pdf

Version: 2024-02-01

234 papers 5,861 citations

71061 41 h-index 59 g-index

240 all docs

240 docs citations

times ranked

240

4063 citing authors

#	Article	IF	CITATIONS
1	Knowledge and beliefs about hepatitis B virus infection and associated factors among Chinese migrants in Australia: The result of a quantitative study. Health and Social Care in the Community, 2022, 30, 918-925.	0.7	9
2	"That was quick, simple, and easy― Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. International Journal of Drug Policy, 2022, 99, 103456.	1.6	14
3	"lt's a revolving door― Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success. International Journal of Drug Policy, 2022, 101, 103571.	1.6	7
4	Hepatitis C cure as a †gathering': Attending to the social and material relations of hepatitis C treatment. Sociology of Health and Illness, 2022, 44, 830-847.	1.1	11
5	A gender lens is needed in hepatitis C elimination research. International Journal of Drug Policy, 2022, 103, 103654.	1.6	10
6	Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project. Harm Reduction Journal, 2022, 19, 40.	1.3	4
7	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy, 2022, 105, 103706.	1.6	14
8	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses, 2022, 14, 1555.	1.5	7
9	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. Drug and Alcohol Dependence, 2022, 237, 109543.	1.6	6
10	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. International Journal of Drug Policy, 2022, 107, 103788.	1.6	18
11	The role of social capital in facilitating hepatitis C treatment scaleâ€up within a treatmentâ€asâ€prevention trial in the male prison setting. Addiction, 2021, 116, 1162-1171.	1.7	6
12	Rethinking the relationship between sex work, mental health and stigma: a qualitative study of sex workers in Australia. Social Science and Medicine, 2021, 268, 113468.	1.8	30
13	People in prison who inject drugs: who is trusted when it comes to information about hepatitis C?. Addiction Research and Theory, 2021, 29, 247-254.	1.2	3
14	Comparing Australian health worker and student attitudes and concerns about providing care to people living with hepatitis B. Health Promotion Journal of Australia, 2021, , .	0.6	3
15	Expert stakeholder perspectives on the acceptability of treatmentâ€asâ€prevention in prison: a qualitative substudy of the †Surveillance and Treatment of Prisoners with Hepatitis C' project (SToP). Addiction, 2021, 116, 2761-2769.	1.7	5
16	Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian â€~surveillance and treatment of prisoners with hepatitis C' project (SToP-C). Harm Reduction Journal, 2021, 18, 46.	1.3	2
17	Australian health and medical workers' concerns around providing care to people living with hepatitis B. Health and Social Care in the Community, 2021, 29, e431-e439.	0.7	4
18	Online interventions to reduce stigma towards population groups affected by blood borne viruses in Australia. International Journal of Drug Policy, 2021, 96, 103292.	1.6	12

#	Article	IF	Citations
19	â€'l Wouldn't Call the Cops if I was Being Bashed to Death': Sex Work, Whore Stigma and the Criminal Legal System. International Journal for Crime, Justice and Social Democracy, 2021, 10, .	0.9	15
20	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2021, 6, 533-546.	3.7	48
21	Priorities and practices of risk reduction among gay and bisexual men in Australia who use crystal methamphetamine for sex. International Journal of Drug Policy, 2021, 93, 103163.	1.6	16
22	Stigma as understood by key informants: A social ecological approach to gay and bisexual men's use of crystal methamphetamine for sex. International Journal of Drug Policy, 2021, 94, 103229.	1.6	16
23	Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia. Journal of Viral Hepatitis, 2021, 28, 1738-1743.	1.0	9
24	Structural competency in the post-prison period for people who inject drugs: A qualitative case study. International Journal of Drug Policy, 2021, 95, 103261.	1.6	15
25	"lt's time!― A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C. International Journal of Drug Policy, 2021, 97, 103280.	1.6	2
26	Positive effects of community attachment on internalised stigma and wellbeing among people who inject drugs. International Journal of Drug Policy, 2021, 97, 103323.	1.6	8
27	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Clinical Infectious Diseases, 2021, 73, e69-e78.	2.9	43
28	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in SMART Recovery Mutual Support Groups: Stage 1 Mixed Methods Pilot Study. Journal of Medical Internet Research, 2021, 23, e25217.	2.1	8
29	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7
30	Commentary on the harm reduction reference group of justice health and forensic mental health network and corrective services NSW, Australia. International Journal of Prisoner Health, 2021, ahead-of-print, .	0.5	0
31	A qualitative exploration of SMART Recovery meetings in Australia and the role of a digital platform to support routine outcome monitoring. Addictive Behaviors, 2020, 101, 106144.	1.7	14
32	â€~C' the potential: needle and syringe programs as hepatitis C treatment sites. Drugs: Education, Prevention and Policy, 2020, 27, 92-94.	0.8	3
33	â€Behind closed doors, no one sees, no one knows': hepatitis C, stigma and treatment-as-prevention in prison. Critical Public Health, 2020, 30, 130-140.	1.4	4
34	The role of social support in moderating the relationship between HIV centrality, internalised stigma and psychological distress for people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 850-857.	0.6	31
35	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
36	HIV stigma by association among Australian gay and bisexual men. Aids, 2020, 34, S53-S61.	1.0	11

#	Article	IF	CITATIONS
37	Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy, 2020, 86, 102964.	1.6	5
38	Identifying risk and protective factors, including culture and identity, for methamphetamine use in Aboriginal and Torres Strait Islander communities: Relevance of the †communities that care†model. Social Science and Medicine, 2020, 266, 113451.	1.8	10
39	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. International Journal of Drug Policy, 2020, 77, 102693.	1.6	12
40	Stigmatising attitudes towards people who inject drugs, and people living with blood borne viruses or sexually transmissible infections in a representative sample of the Australian population. PLoS ONE, 2020, 15, e0232218.	1,1	25
41	Destabilising the †problem' of chemsex: Diversity in settings, relations and practices revealed in Australian gay and bisexual men's crystal methamphetamine use. International Journal of Drug Policy, 2020, 78, 102697.	1.6	42
42	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study. JMIR Research Protocols, 2020, 9, e15113.	0.5	8
43	Violence and hepatitis C transmission in prison—A modified social ecological model. PLoS ONE, 2020, 15, e0243106.	1.1	4
44	â€~Fighting a losing battle': prisoners' perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures. Drugs: Education, Prevention and Policy, 2019, 26, 502-507.	0.8	3
45	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 2019, 72, 1-10.	1.6	40
46	Involving peers in research: the UNSW community reference panel. Harm Reduction Journal, 2019, 16, 52.	1.3	3
47	Making sense of â€~side effects': Counterpublic health in the era of direct-acting antivirals. International Journal of Drug Policy, 2019, 72, 77-83.	1.6	31
48	Enhancing engagement in hepatitis C care among people who inject drugs. Addiction, 2019, 114, 2104-2106.	1.7	4
49	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	1.0	25
50	Predictors of health care workers' support for discriminatory treatment and care of people who inject drugs. Psychology, Health and Medicine, 2019, 24, 439-445.	1.3	17
51	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy, 2019, 66, 87-93.	1.6	20
52	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	1.9	88
53	Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs. Patient, 2019, 12, 259-265.	1.1	9
54	Lives of Substance: a mixed-method evaluation of a public information website on addiction experiences. Drugs: Education, Prevention and Policy, 2019, 26, 140-147.	0.8	3

#	Article	IF	CITATIONS
55	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health, 2019, 29, 260-273.	1.4	14
56	A Web-Based Therapeutic Program (We Can Do This) for Reducing Methamphetamine Use and Increasing Help-Seeking Among Aboriginal and Torres Strait Islander People: Protocol for a Randomized Wait-List Controlled Trial. JMIR Research Protocols, 2019, 8, e14084.	0.5	4
57	The rush to risk when interrogating the relationship between methamphetamine use and sexual practice among gay and bisexual men. International Journal of Drug Policy, 2018, 55, 242-248.	1.6	51
58	Evaluation of the Deadly Liver Mob program: insights for roll-out and scale-up of a pilot program to engage Aboriginal Australians in hepatitis C and sexual health education, screening, and care. Harm Reduction Journal, 2018, 15, 5.	1.3	24
59	Do women with complex alcohol and other drug use histories want womenâ€only residential treatment?. Addiction, 2018, 113, 989-997.	1.7	31
60	Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug and Alcohol Dependence, 2018, 183, 96-101.	1.6	18
61	Practices of partnership: Negotiated safety among couples who inject drugs. Health (United Kingdom), 2018, 22, 3-19.	0.9	29
62	Health protection and Australian prisons, 2018. Medical Journal of Australia, 2018, 209, 460.	0.8	3
63	Responding to a national policy need: development of a stigma indicator for bloodborne viruses and sexually transmissible infections. Australian and New Zealand Journal of Public Health, 2018, 42, 513-515.	0.8	25
64	Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?. PLoS ONE, 2018, 13, e0207226.	1.1	77
65	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	1.6	57
66	Measuring Social Capital in the Prison Setting: Lessons Learned From the Inmate Social Capital Questionnaire. Journal of Correctional Health Care, 2018, 24, 407-417.	0.2	44
67	Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduction Journal, 2018, 15, 42.	1.3	45
68	Building on feminist achievements to enhance choice for women seeking treatment. Addiction, 2018, 113, 1001-1002.	1.7	0
69	Understanding facilitators and barriers of directâ€acting antiviral therapy for hepatitis C virus infection in prison. Journal of Viral Hepatitis, 2018, 25, 1526-1532.	1.0	44
70	A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons. Harm Reduction Journal, 2018, 15, 39.	1.3	8
71	HCV knowledge among a sample of HCV positive Aboriginal Australians residing in New South Wales. Psychology, Health and Medicine, 2017, 22, 625-632.	1.3	3
72	"Don't think l'm going to leave you over it― Accounts of changing hepatitis C status among couples who inject drugs. Drug and Alcohol Dependence, 2017, 173, 78-84.	1.6	17

#	Article	IF	Citations
73	â€~Naloxone works': The politics of knowledge in â€~evidence-based' drug policy. Health (United Kingdom 2017, 21, 278-294.) _{0.9}	33
74	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. Addiction, 2017, 112, 1126-1127.	1.7	2
75	Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis. International Journal of Drug Policy, 2017, 44, 192-201.	1.6	109
76	The intimate relationship as a site of social protection: Partnerships between people who inject drugs. Social Science and Medicine, 2017, 180, 125-134.	1.8	26
77	â€~Affording' new approaches to couples who inject drugs: A novel fitpack design for hepatitis C prevention. International Journal of Drug Policy, 2017, 50, 19-35.	1.6	17
78	Afterword. International Journal of Drug Policy, 2017, 49, 171-172.	1.6	3
79	Young people at risk of transitioning to injecting: what do they know about where to get sterile needles?. Vulnerable Children and Youth Studies, 2017, 12, 138-146.	0.5	1
80	Evaluation of an online injecting drug use stigma intervention targeted at health providers in New South Wales, Australia. Health Psychology Open, 2017, 4, 205510291770718.	0.7	29
81	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy, 2017, 47, 26-33.	1.6	53
82	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 2017, 11, 10-18.	1.4	9
83	â€1 didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy, 2017, 47, 153-160.	1.6	10
84	"l Had a Little Bit of a Bloke Meltdown…But the Next Day, I Was Up― Cancer Nursing, 2017, 40, E1-E8.	0.7	7
85	<i>â€~lt's Fast, lt's Quick, lt Stops Me Being Sick'</i> : How to influence preparation of opioid tablets for injection. Drug and Alcohol Review, 2017, 36, 651-657.	1.1	4
86	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	1.6	54
87	Listening to the consumer voice: developing multilingual cancer information resources for people affected by liver cancer. Health Expectations, 2017, 20, 171-182.	1.1	8
88	Diffracting addicting binaries: An analysis of personal accounts of alcohol and other drug $\hat{a} \in \mathbb{R}^m$. Health (United Kingdom), 2017, 21, 519-537.	0.9	32
89	The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?. PLoS ONE, 2016, 11, e0162399.	1.1	23
90	Sexual identity and its relationship to injecting in a sample of disadvantaged young drug users. Drug and Alcohol Review, 2016, 35, 218-222.	1.1	3

#	Article	IF	CITATIONS
91	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open, 2016, 4, E605-E614.	1.1	74
92	Hepatitis C prevention and convenience: why do people who inject drugs in sexual partnerships â€~run out' of sterile equipment?. Critical Public Health, 2016, 26, 294-306.	1.4	11
93	Harm reduction workers and the challenge of engaging couples who inject drugs in hepatitis C prevention. Drug and Alcohol Dependence, 2016, 168, 170-175.	1.6	4
94	Experiences of diagnosis, care and treatment among Aboriginal people living with hepatitis C. Australian and New Zealand Journal of Public Health, 2016, 40, S59-S64.	0.8	21
95	Contextualising the social capital of Australian Aboriginal and non-Aboriginal men in prison. Social Science and Medicine, 2016, 167, 29-36.	1.8	14
96	Exposure to injecting drug use and hepatitis C knowledge among an online sample of young people. Drugs: Education, Prevention and Policy, 2016, 23, 84-88.	0.8	1
97	Beyond equipment distribution in Needle and Syringe Programmes: an exploratory analysis of blood-borne virus risk and other measures of client need. Harm Reduction Journal, 2016, 13, 18.	1.3	14
98	Unlocking dimensions of social capital in the prison setting. Health and Justice, 2016, 4, 9.	0.9	12
99	Deconstructing injecting risk of hepatitis C virus transmission: Using strategic positioning to understand "higher risk―practices. Drugs: Education, Prevention and Policy, 2016, 23, 457-461.	0.8	2
100	Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs. International Journal of Drug Policy, 2016, 27, 138-145.	1.6	76
101	"We get by with a little help from our friends― Small-scale informal and large-scale formal peer distribution networks of sterile injecting equipment in Australia. International Journal of Drug Policy, 2016, 34, 65-71.	1.6	17
102	Understanding decisions made about hepatitis C treatment by couples who inject drugs. Journal of Viral Hepatitis, 2016, 23, 89-95.	1.0	7
103	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 2016, 111, 311-319.	1.7	63
104	Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C. Health Sociology Review, 2016, 25, 18-32.	1.7	40
105	Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments. Ethnicity and Health, 2016, 21, 39-57.	1.5	22
106	"Doing the devil's work― Emotional labour and stigma in expanding Needle and Syringe Programs. Drugs: Education, Prevention and Policy, 2015, 22, 437-443.	0.8	10
107	The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis. Health Psychology Open, 2015, 2, 205510291560158.	0.7	14
108	Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduction Journal, 2015, 12, 10.	1.3	21

#	Article	IF	Citations
109	Salvaging a prison needle and syringe program trial in Australia requires leadership and respect for evidence. Medical Journal of Australia, 2015, 203, 319-320.	0.8	14
110	A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations. Harm Reduction Journal, 2015, 12, 5.	1.3	4
111	New narratives, new selves: Complicating addiction in online alcohol and other drug resources. Addiction Research and Theory, 2015, 23, 499-509.	1.2	25
112	Laws prohibiting peer distribution of injecting equipment in Australia: A critical analysis of their effects. International Journal of Drug Policy, 2015, 26, 1198-1206.	1.6	58
113	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 2015, 26, 1094-1102.	1.6	18
114	Discrimination by health care workers versus discrimination by others: Countervailing forces on HCV treatment intentions. Psychology, Health and Medicine, 2015, 20, 148-153.	1.3	20
115	Commentary on Historical Trauma, Substance Use, and Indigenous People: Seven Generations From a "Big Event― Substance Use and Misuse, 2015, 50, 891-893.	0.7	2
116	Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 893-898.	1.6	33
117	Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs. International Journal of Drug Policy, 2015, 26, 1039-1040.	1.6	0
118	Young people at risk of transitioning to injecting drug use in Sydney, Australia: social disadvantage and other correlates of higher levels of exposure to injecting. Health and Social Care in the Community, 2015, 23, 200-207.	0.7	7
119	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 2015, 26, 992-998.	1.6	65
120	Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 2015, 26, 999-1006.	1.6	43
121	"We are people too†Consumer participation and the potential transformation of therapeutic relations within drug treatment. International Journal of Drug Policy, 2015, 26, 30-36.	1.6	57
122	What's the Cost of Finding the Right Fit? The Cost of Conducting NSP Business in a Range of Modalities. Contemporary Drug Problems, 2014, 41, 41-56.	0.7	4
123	Hepatitis C prevention education needs to be grounded in social relationships. Drugs: Education, Prevention and Policy, 2014, 21, 88-92.	0.8	25
124	Not just Methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction, 2014, 109, 452-459.	1.7	29
125	"l can't do this, it's too much― building social inclusion in cancer diagnosis and treatment experiences of Aboriginal people, their carers and health workers. International Journal of Public Health, 2014, 59, 373-379.	1.0	37
126	How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. International Journal of Drug Policy, 2014, 25, 865-870.	1.6	43

#	Article	IF	CITATIONS
127	Barriers and facilitators for assessment and treatment of hepatitis $\langle scp \rangle C \langle scp \rangle$ virus infection in the opioid substitution treatment setting: insights from the $\langle scp \rangle ETHOS \langle scp \rangle$ study. Journal of Viral Hepatitis, 2014, 21, 560-567.	1.0	53
128	Perceived discrimination and injecting risk among people who inject drugs attending Needle and Syringe Programmes in Sydney, Australia. Drug and Alcohol Dependence, 2014, 144, 274-278.	1.6	42
129	Mental health support workers' attitudes towards hepatitis C and injecting drug use: barriers to recovery?. Mental Health and Substance Use: Dual Diagnosis, 2014, 7, 217-229.	0.5	2
130	A piece of the jigsaw of primary care: health professional perceptions of an integrated care model of hepatitis C management in the community. Journal of Primary Health Care, 2014, 6, 129.	0.2	8
131	A piece of the jigsaw of primary care: health professional perceptions of an integrated care model of hepatitis C management in the community. Journal of Primary Health Care, 2014, 6, 129-34.	0.2	4
132	Response to Chandler et al., Substance, structure and stigma: Parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods. International Journal of Drug Policy, 2013, 24, e87-e88.	1.6	4
133	Examining structural violence in opioid pharmacotherapy treatment in Australia: Sweating the "small stuff―in a liberal paradise. International Journal of Drug Policy, 2013, 24, e11-e13.	1.6	14
134	Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug and Alcohol Dependence, 2013, 133, 529-534.	1.6	26
135	â€~Makes you wanna do treatment': Benefits of a hepatitis C specialist clinic to clients in Christchurch, New Zealand. Health and Social Care in the Community, 2013, 21, 216-223.	0.7	10
136	International Policies to Reduce Illicit Drug-Related Harm and Illicit Drug Use., 2013,, 735-743.		1
137	Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 2013, 57, S62-S69.	2.9	97
138	Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. Clinical Infectious Diseases, 2013, 57, S51-S55.	2.9	161
139	Peer education for people who inject drugs in New South Wales: Advantages, unanticipated benefits and challenges. Drugs: Education, Prevention and Policy, 2013, 20, 304-311.	0.8	12
140	<i><scp>A</scp>ddiction</i> journal is committed to publishing qualitative research. Addiction, 2013, 108, 447-449.	1.7	21
141	At the intersection of marginalised identities: lesbian, gay, bisexual and transgender people's experiences of injecting drug use and hepatitis C seroconversion. Health and Social Care in the Community, 2013, 21, 402-410.	0.7	23
142	Health literacy in relation to cancer: addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services. Health and Social Care in the Community, 2013, 21, n/a-n/a.	0.7	31
143	Authenticity and Diversity: Enhancing Australian Hepatitis C Prevention Messages. Contemporary Drug Problems, 2013, 40, 505-529.	0.7	11
144	One size fits all? The discursive framing of cultural difference in health professional accounts of providing cancer care to Aboriginal people. Ethnicity and Health, 2013, 18, 433-447.	1.5	21

#	Article	IF	Citations
145	Knowledge and attitudes towards hepatitis C and injecting drug use among mental-health support workers of a community managed organisation. Australian Health Review, 2013, 37, 654.	0.5	2
146	Under the watchful eye of 'a benevolent dictator' - general practitioner and patient experiences of hepatitis C treatment initiation and shared-care in general practice. Australian Family Physician, 2013, 42, 900-3.	0.5	12
147	Structural constraints on the training of peer educators in hepatitis C prevention. Health Education Research, 2012, 27, 248-257.	1.0	7
148	Staying Safe From Hepatitis C. Qualitative Health Research, 2012, 22, 31-42.	1.0	24
149	Rethinking safety and fidelity: The role of love and intimacy in hepatitis C transmission and prevention. Health Sociology Review, 2012, 21, 272-286.	1.7	33
150	Health worker attitudes toward peer workers in hepatitis C prevention. Psychology, Health and Medicine, 2012, 17, 659-666.	1.3	4
151	Harm minimisation in Australian prisons — health protection still depends on where you serve your time. Medical Journal of Australia, 2012, 197, 382-382.	0.8	5
152	The politics of place(ment): Problematising the provision of hepatitis C treatment within opiate substitution clinics. Social Science and Medicine, 2012, 74, 245-253.	1.8	31
153	Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug and Alcohol Review, 2012, 31, 918-924.	1.1	63
154	Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand. International Journal of Integrated Care, 2012, 12, e229.	0.1	13
155	Evaluation of Consumer Participation Demonstration Projects in Five Australian Drug User Treatment Facilities: The Impact of Individual Versus Organizational Stability in Determining Project Progress. Substance Use and Misuse, 2011, 46, 969-979.	0.7	15
156	Hepatitis C, love and intimacy: Beyond the â€~anomalous body'. Drugs: Education, Prevention and Policy, 2011, 18, 228-236.	0.8	12
157	Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug and Alcohol Dependence, 2011, 116, 52-56.	1.6	42
158	Social inclusion and hepatitis C: exploring new possibilities for prevention. Expert Review of Anti-Infective Therapy, 2011, 9, 397-404.	2.0	7
159	Doing things together? Analysis of health education materials to inform hepatitis C prevention among couples. Addiction Research and Theory, 2011, 19, 352-361.	1.2	24
160	Preventing transitions to injecting amongst young people: What is the role of Needle and Syringe Programmes?. International Journal of Drug Policy, 2010, 21, 160-164.	1.6	9
161	Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. Journal of Viral Hepatitis, 2010, 17, 839-844.	1.0	92
162	The proof is in the toothpaste: police ordered exclusion as a result of research participation. Australian and New Zealand Journal of Public Health, 2010, 34, 533-534.	0.8	1

#	Article	IF	CITATIONS
163	Assessing community support for harm reduction services: Comparing two measures. Drug and Alcohol Review, 2010, 29, 385-391.	1.1	17
164	Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in southâ€east Sydney. Drug and Alcohol Review, 2010, 29, 364-370.	1.1	22
165	Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: Utility of a mixed methods approach. Drug and Alcohol Review, 2010, 29, 491-497.	1.1	108
166	Hepatitis C in an Australian Migrant Community: Knowledge of and Attitudes towards Transmission and Infection. Contemporary Drug Problems, 2010, 37, 659-683.	0.7	2
167	Disclosing Hepatitis C Infection Within Everyday Contexts. Journal of Health Psychology, 2010, 15, 811-818.	1.3	21
168	Working with the "hierarchy in the Underworld†Insights for Communication Skills Training with Peer Educators. Contemporary Drug Problems, 2010, 37, 639-657.	0.7	5
169	†Does anyone know where to get fits from around here?†Policy implications for the provision of sterile injecting equipment through pharmacies in Sydney, Australia. Drugs: Education, Prevention and Policy, 2010, 17, 72-83.	0.8	10
170	Normalisation of recreational drug use among young people: Evidence about accessibility, use and contact with other drug users. Health Sociology Review, 2010, 19, 164-175.	1.7	22
171	Using mindfulness to develop health education strategies for blood borne virus prevention in injecting drug use. Drugs: Education, Prevention and Policy, 2010, 17, 431-442.	0.8	10
172	Needle sharing in regular sexual relationships: An examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug and Alcohol Dependence, 2010, 107, 182-187.	1.6	88
173	"Fitness for duty― Social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine, 2010, 28, 5228-5236.	1.7	16
174	A diagnosis of hepatitis C - insights from a study on patients' experiences. Australian Family Physician, 2010, 39, 589-92.	0.5	20
175	The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis. Qualitative Health Research, 2009, 19, 1321-1334.	1.0	85
176	Indigenous Australian medical students' perceptions of their medical school training. Medical Education, 2009, 43, 1047-1055.	1.1	32
177	Hepatitis C treatment in pharmacotherapy services: Increasing treatment uptake needs a critical view. Drug and Alcohol Review, 2009, 28, 436-440.	1.1	17
178	Exploring the role of consumer participation in drug treatment. Drug and Alcohol Dependence, 2009, 105, 172-175.	1.6	33
179	Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment. Australian Health Review, 2009, 33, 100.	0.5	10
180	Managing Mental Health Problems in Everyday Life: Drug Treatment Clients' Self-Care Strategies. International Journal of Mental Health and Addiction, 2008, 6, 421-431.	4.4	11

#	Article	IF	CITATIONS
181	Initiators: An Examination of Young Injecting Drug Users Who Initiate Others to Injecting. AIDS and Behavior, 2008, 12, 885-890.	1.4	40
182	The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction, 2008, 103, 1593-1603.	1.7	103
183	Broadening discussions of "safe―in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice. International Journal of Drug Policy, 2008, 19, 59-65.	1.6	29
184	Pleasure and drugs. International Journal of Drug Policy, 2008, 19, 349-352.	1.6	63
185	Understanding comorbidity? Australian service-user and provider perspectives on drug treatment and mental-health literacy. Drugs: Education, Prevention and Policy, 2008, 15, 518-531.	0.8	3
186	Cancer and Aboriginal people in Australia: A review of the literature. Critical Public Health, 2008, 18, 65-75.	1.4	19
187	"Look, I'm fit, I'm positive and I'll be all right, thank you very much― Coping with hepatitis C treatment and unrealistic optimism. Psychology, Health and Medicine, 2008, 13, 360-366.	1.3	20
188	Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities. Mental Health and Substance Use: Dual Diagnosis, 2008, 1, 84-95.	0.5	28
189	Resilient Coping. Journal of Health Psychology, 2008, 13, 17-27.	1.3	28
190	Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Australian Health Review, 2008, 32, 570.	0.5	33
191	Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice. Drugs: Education, Prevention and Policy, 2007, 14, 61-74.	0.8	45
192	Chronic Illness Experiences, Clinical Markers and Living with Hepatitis C. Journal of Health Psychology, 2007, 12, 330-340.	1.3	38
193	Prisons, hepatitis C and harm minimisation. Medical Journal of Australia, 2007, 186, 647-649.	0.8	17
194	Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. Journal of Advanced Nursing, 2007, 59, 248-254.	1.5	11
195	Equity of access to treatment, and barriers to treatment for illicit drug use in Australia. Addiction, 2007, 102, 958-969.	1.7	53
196	The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. International Journal of Drug Policy, 2007, 18, 374-380.	1.6	21
197	How can hepatitis C be prevented in the long term?. International Journal of Drug Policy, 2007, 18, 338-340.	1.6	35
198	The gendered context of initiation to injecting drug use: evidence for women as active initiates. Drug and Alcohol Review, 2007, 26, 287-293.	1,1	63

#	Article	IF	CITATIONS
199	Public opinion on needle and syringe programmes: avoiding assumptions for policy and practice. Drug and Alcohol Review, 2007, 26, 355-361.	1.1	38
200	Applied communitarian ethics for harm reduction: promoting a dialogue within the field. Drug and Alcohol Review, 2007, 26, 553-555.	1.1	5
201	Representations of people with HIV and hepatitis C in editorials of medical journals: Discourses and interdiscursive relations. Communication and Medicine, 2006, 3, 15-25.	0.1	6
202	Some characteristics of early-onset injection drug users prior to and at the time of their first injection. Addiction, 2006, 101, 548-555.	1.7	72
203	Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug and Alcohol Review, 2006, 25, 439-444.	1.1	30
204	Risk practices and other characteristics of injecting drug users who obtain injecting equipment from pharmacies and personal networks. International Journal of Drug Policy, 2006, 17, 418-424.	1.6	19
205	Hepatitis C and injecting-related discrimination in New South Wales, Australia. Drugs: Education, Prevention and Policy, 2006, 13, 61-75.	0.8	41
206	Deficit models and divergent philosophies: Service providers' perspectives on barriers and incentives to drug treatment. Drugs: Education, Prevention and Policy, 2006, 13, 367-382.	0.8	58
207	â€~Spoiled identity' in hepatitis C infection: The binary logic of despair. Critical Public Health, 2006, 16, 99-110.	1.4	76
208	Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics. Drug and Alcohol Review, 2005, 24, 449-459.	1.1	46
209	NSPs and the media: a case study of balanced and accurate reporting?. Australian and New Zealand Journal of Public Health, 2005, 29, 489-490.	0.8	7
210	Information exchange among injecting drug users: a role for an expanded peer education workforce. International Journal of Drug Policy, 2005, 16 , $46-53$.	1.6	38
211	Barriers to use of Needle and Syringe Programmes in a high drug use area of Sydney, New South Wales. International Journal of Drug Policy, 2005, 16, 308-315.	1.6	35
212	Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer. Supportive Care in Cancer, 2005, 13, 895-903.	1.0	11
213	Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia. Clinical Infectious Diseases, 2005, 40, S313-S320.	2.9	133
214	â€~You Sort of Switch Off': Exploring Mindlessness in Injecting Drug Users' Accounts of Blood. Journal of Health Psychology, 2005, 10, 137-145.	1.3	9
215	Incorporating the message: Research dissemination with the injecting drug use field. International Journal of Health Promotion and Education, 2005, 43, 75-80.	0.4	2
216	The Experience of Interferon-Based Treatments for Hepatitis C Infection. Qualitative Health Research, 2005, 15, 635-646.	1.0	39

#	Article	IF	CITATIONS
217	The power of naming: A reply to McBride and Pates. Addiction Research and Theory, 2005, 13, 403-404.	1.2	4
218	Single index of multimorbidity did not predict multiple outcomes. Journal of Clinical Epidemiology, 2005, 58, 997-1005.	2.4	95
219	Hepatitis C, blood and models of the body: New directions for public health. Critical Public Health, 2004, 14, 377-389.	1.4	15
220	Needle fictions: medical constructions of needle fixation and the injecting drug user. Addiction Research and Theory, 2004, 12, 67-76.	1.2	17
221	Blood and bioidentity: ideas about self, boundaries and risk among blood donors and people living with Hepatitis C. Social Science and Medicine, 2004, 59, 1461-1471.	1.8	70
222	Needle and syringe programmes in the local media: "needle anger―versus "effective education in the community― International Journal of Drug Policy, 2004, 15, 46-55.	1.6	29
223	Infection Control in the Context of Hepatitis C Disclosure: Implications for Education of Healthcare Professionals. Education for Health: Change in Learning and Practice, 2004, 17, 183-191.	0.1	30
224	Evaluation of an instrument to assess the needs of men diagnosed with prostate carcinoma. Cancer, 2003, 97, 993-1001.	2.0	11
225	Rural General Practitioner Apprehension About Work Related Violence in Australia. Australian Journal of Rural Health, 2003, 11, 237-241.	0.7	18
226	Multidisciplinary Cross-National Studies: A Commentary on Issues of Collaboration, Methodology, Analysis, and Publication. Qualitative Health Research, 2003, 13, 924-932.	1.0	21
227	Hepatitis Câ€related discrimination in healthcare. Medical Journal of Australia, 2002, 177, 233-234.	0.8	22
228	Prediction of intern attendance at a seminar-based training programme: a behavioural intention model. Medical Education, 2000, 34, 512-518.	1.1	14
229	Factors affecting progress of Australian and international students in a problem-based learning medical course. Medical Education, 2000, 34, 708-715.	1.1	43
230	Critical appraisal checklist for qualitative research studies. Indian Journal of Pediatrics, 2000, 67, 347-351.	0.3	35
231	Use of interventions to minimise perioperative allogeneic blood transfusion in Australia A survey by the International Study of Perioperative Transfusion (ISPOT) study group. Medical Journal of Australia, 2000, 172, 365-369.	0.8	16
232	An 'Academic Detailing' Intervention To Decrease Exposure to HIV Infection among Health-care Workers. Journal of Health Psychology, 1996, 1, 455-468.	1.3	6
233	Overdoselifesavers.org: a mixed-method evaluation of a public information website on experiences of overdose and using take-home naloxone to save lives. Drugs: Education, Prevention and Policy, 0, , 1-11.	0.8	1
234	â€Even though you hate everything that's going on, you know they are safer at home': The role of Aboriginal and Torres Strait Islander families in methamphetamine use harm reduction and their own support needs. Drug and Alcohol Review, 0, , .	1.1	4